Treatment of Subacute Pulmonary Embolism

Initial Assessment and Risk Stratification

The European Society of Cardiology recommends risk stratification to determine appropriate treatment, categorizing patients as high-risk, intermediate-risk, or low-risk based on hemodynamic stability, right ventricular function, and cardiac biomarkers 2, 3
Subacute pulmonary embolism typically falls into intermediate or low-risk categories, characterized by hemodynamic stability but may have evidence of right ventricular dysfunction 4
Bedside echocardiography or emergency CTPA should be performed for diagnosis, depending on clinical circumstances and availability 2, 5

The European Heart Journal recommends initiating anticoagulation immediately while diagnostic workup is ongoing if clinical suspicion is high or intermediate 1, 2
For patients without hemodynamic instability, low molecular weight heparin or fondaparinux is preferred over unfractionated heparin 2, 3
Unfractionated heparin should be considered in patients with severe renal impairment or if thrombolysis might be needed 6
The European Society of Cardiology recommends direct oral anticoagulants, such as apixaban, dabigatran, edoxaban, or rivaroxaban, over vitamin K antagonists for eligible patients 2, 3
If direct oral anticoagulants are contraindicated, vitamin K antagonists should be used overlapping with parenteral anticoagulation until an INR of 2.0-3.0 is reached 2, 3

The European Heart Journal recommends administering therapeutic anticoagulation for at least 3 months to all patients with pulmonary embolism 2, 3
After 3 months, the patient should be assessed for discontinuation of therapy, indefinite anticoagulation, or extended anticoagulation based on individual risk-benefit assessment 1, 2

Thrombolysis is not routinely recommended for subacute pulmonary embolism, but may be considered if hemodynamic deterioration occurs during anticoagulation treatment 2, 3
Inferior vena cava filters are not routinely recommended, but may be considered in patients with absolute contraindications to anticoagulation or recurrent pulmonary embolism despite adequate anticoagulation 1, 2, 3

The European Society of Cardiology recommends scheduling follow-up examination after 3-6 months of anticoagulation to assess for signs of venous thromboembolism recurrence, bleeding complications, and persistent or new-onset dyspnea or functional limitations 1
If persistent symptoms are present, diagnostic workup should be implemented to exclude chronic thromboembolic pulmonary hypertension 1

Delaying anticoagulation while awaiting diagnostic confirmation in patients with high clinical probability should be avoided 1, 2
Using direct oral anticoagulants in patients with severe renal impairment or antiphospholipid antibody syndrome should be avoided 2, 3
Routinely administering thrombolysis for subacute pulmonary embolism without hemodynamic compromise should be avoided 2, 3
Losing patients to follow-up after initial treatment, risking missed chronic thromboembolic pulmonary hypertension diagnosis, should be avoided 1
Overlooking the need to reassess the risk-benefit ratio of continued anticoagulation after the initial treatment period should be avoided 1, 2